@article {Castro2021.09.28.21264259, author = {Victor M. Castro and Faith M. Gunning and Roy H. Perlis}, title = {Persistence of neuropsychiatric symptoms associated with SARS-CoV-2 positivity among a cohort of children and adolescents}, elocation-id = {2021.09.28.21264259}, year = {2021}, doi = {10.1101/2021.09.28.21264259}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Post-acute sequelae of COVID-19 are common among adults. The prevalence of such syndromes among community samples of children and adolescents remains less well characterized.Method We identified all individuals age 5-18 across 2 New England health systems who had a positive SARS-CoV-2 PCR test between 3/12/2020 and 4/18/2021 and at least 90 days of follow-up visits documented in electronic health records. We identified neuropsychiatric symptoms in intervals prior to, and following, this testing using a previously-derived set of ICD-10 codes and natural language processing terms. Primary analysis examined sociodemographic features associated with presence of at least one incident (i.e., new-onset) neuropsychiatric symptom between 90 and 150 days after an initial positive test for COVID-19.Results Among 5058 children (50\% female, 2.9\% Asian, 6.3\% Black, and 63\% White; 30\% Hispanic; mean age was 12.4 (IQR 8.9-15.6), 366 (7.2\%) exhibited at least one new-onset neuropsychiatric symptom between 90 and 150 days following initial SARS-CoV-2 test positivity. The most common incident symptoms at 90-150 days were headache (2.4\%), mood and anxiety symptoms (2.4\%), cognitive symptoms (2.3\%), and fatigue (1.1\%). In regression models, older children, girls, those with Hispanic ethnicity, those with public versus private insurance, and those with greater overall burden of medical comorbidity were more likely to exhibit subsequent symptoms.Conclusion The prevalence of neuropsychiatric symptoms between 3- and 5-months following SARS-CoV-2 test positivity is similar to that observed in the period prior to infection. Prospective controlled studies will be needed to further refine these estimates.Competing Interest StatementThis study was supported by the National Institute of Mental Health (R01MH120227, R01MH116270; Dr. Perlis). The sponsors did not contribute to any aspect of study design, data collection, data analysis, or data interpretation. The authors had the final responsibility for the decision to submit for publication. RHP holds equity in Psy Therapeutics and Belle-Torus Artificial Intelligence; serves on scientific advisory boards of Genomind, Psy Therapeutics, Belle-Torus Artificial Intelligence, and Takeda; and consults to RID Ventures and Burrage Capital. Funding StatementThis study was supported by the National Institute of Mental Health (R01MH120227, R01MH116270; Dr. Perlis). The sponsors did not contribute to any aspect of study design, data collection, data analysis, or data interpretation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Committee of Mass General-Brigham granted a waiver of informed consent requirement for this research protocol under 45 CFR 46.116, as only secondary use of data generated by routine clinical care was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPer IRB approval, data cannot be released to outside investigators without permission.}, URL = {https://www.medrxiv.org/content/early/2021/09/29/2021.09.28.21264259}, eprint = {https://www.medrxiv.org/content/early/2021/09/29/2021.09.28.21264259.full.pdf}, journal = {medRxiv} }